SCHEDULE: BlackRock Amends Stake in ORIC Pharmaceuticals, Reports 4.2% Beneficial Ownership
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.2% beneficial ownership stake in ORIC PHARMACEUTICALS INC as of June 30, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in ORIC PHARMACEUTICALS INC.
- As of June 30, 2025, BlackRock, Inc. beneficially owns an aggregate of 3,620,224 shares of ORIC PHARMACEUTICALS INC Common Stock.
- This ownership represents 4.2% of the total outstanding class of securities.
- BlackRock, Inc. holds sole voting power over 3,541,081 shares and sole dispositive power over 3,620,224 shares.
- No shared voting or dispositive power is reported by BlackRock, Inc.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain positive or negative operational or financial news for the issuer. The sentiment is neutral as it simply reports a stake held by an institutional investor.
Positives
- A major institutional investor, BlackRock, Inc., holds a significant stake in ORIC PHARMACEUTICALS INC, indicating institutional interest.
- BlackRock's holding is for investment purposes in the ordinary course of business, not for control, suggesting a stable, passive investment perspective.
Negatives
- The document is a routine ownership disclosure and does not contain negative information regarding ORIC PHARMACEUTICALS INC's operational or financial performance.
Risks
- The document does not explicitly state risks related to ORIC PHARMACEUTICALS INC's operations or financial health. It notes that no single person's interest in the common stock of ORIC PHARMACEUTICALS INC is more than five percent of the total outstanding common shares.
Future Outlook
The document does not provide forward-looking statements or guidance regarding ORIC PHARMACEUTICALS INC's future performance or strategic direction.
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
Industry Context
This filing is a routine disclosure of institutional ownership by BlackRock, Inc. and does not provide specific industry context or trends for the pharmaceutical sector. It reflects BlackRock's investment allocation decisions within its managed portfolios.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence investor perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-06-30 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-07-17 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
ORIC PHARMACEUTICALS INC, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.